Vincent P Marshall

42647266, Apr 28, 1981

Mar 12, 1980

6/129532

Vincent P. Marshall - Portage MI
David W. Elrod - Portage MI
Paul F. Wiley - Portage MI

The Upjohn Company - Kalamazoo MI

C12P 1946
C12N 114

435 78

Antibiotics 10-dihydrosteffimycin (U-58,875), and 10-dihydrosteffimycin B (U-58,874) are produced by carbon 10 ketonic carbonyl reduction in fermentation processes using the known antibiotics steffimycin and steffimycin B, respectively, as starting materials. These novel antibiotics are active against various microorganisms, for example, Bacillus subtilis, Bacillus cereus, Sarcina lutea, Streptococcus pyogenes, and Mycobacterium avium. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

40778444, Mar 7, 1978

Mar 30, 1977

5/782621

Vincent P. Marshall - Portage MI
David W. Elrod - Kalamazoo MI
James M. Koert - Kalamazoo MI
Elizabeth A. Reisender - Kalamazoo MI
Paul F. Wiley - Kalamazoo MI

The Upjohn Company - Kalamazoo MI

C12D 918

195 80R

Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, there antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

42096111, Jun 24, 1980

Apr 6, 1979

6/027878

Vincent P. Marshall - Portage MI
David W. Elrod - Portage MI
Paul F. Wiley - Portage MI

The Upjohn Company - Kalamazoo MI

C07H 1524

536 17A

Antibiotics 10-dihydrosteffimycin (U-58,875), and 10-dihydrosteffimycin B (U-58,874) are produced by carbon 10 ketonic carbonyl reduction in fermentation processes using the known antibiotics steffimycin and steffimycin B, respectively, as starting materials. These novel antibiotics are active against various microorganisms, for example, Bacillus subtilis, Bacillus cereus, Sarcina lutea, Streptococcus pyogenes, and Mycobacterium avium. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

41069943, Aug 15, 1978

Nov 16, 1977

5/851866

Vincent P. Marshall - Portage MI
David W. Elrod - Kalamazoo MI
James M. Koert - Kalamazoo MI
Elizabeth A. Reisender - Kalamazoo MI
Paul F. Wiley - Kalamazoo MI

The Upjohn Company - Kalamazoo MI

C12D 914

195 80R

Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

45058954, Mar 19, 1985

Mar 30, 1983

6/480604

Alexander D. Argoudelis - Portage MI
Vincent P. Marshall - Kalamazoo MI
Paul F. Wiley - Portage MI

The Upjohn Company - Kalamazoo MI

A61K 3574
C12P 106

424117

Novel and useful antibiotics designated 273a. sub. 1. spsb. alpha. and 273a. sub. 1. spsb. beta. can be produced in a fermentation using Streptomyces paulus, strain 273, NRRL 12251. These antibiotics are active against various Gram-positive bacteria. Also, these antibiotics are, advantageously, soluble in aqueous solutions.

44304951, Feb 7, 1984

Sep 17, 1982

6/419244

Tom E. Patt - Kalamazoo MI
Alexander D. Argoudelis - Portage MI
Vincent P. Marshall - Kalamazoo MI

The Upjohn Company - Kalamazoo MI

C07H 1516

536 163

Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clindamycin. These ribonucleotides are unexpectedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo. These ribonucleotides are prepared by using resting cell or cell-free extracts of Streptomyces rochei, NRRL 3533, or cell-free extracts of Streptomyces coelicolor, NRRL 3532.

41167694, Sep 26, 1978

Nov 16, 1977

5/851861

Vincent P. Marshall - Portage MI
David W. Elrod - Kalamazoo MI
James M. Koert - Kalamazoo MI
Elizabeth A. Reisender - Kalamazoo MI
Paul F. Wiley - Kalamazoo MI

The Upjohn Company - Kalamazoo MI

C12D 920

195 51R

Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

56439407, Jul 1, 1997

May 1, 1995

8/432374

George Anthony Conder - Richland MI
Ming-Shang Thomas Kuo - Portage MI
Vincent P. Marshall - Kalamazoo MI
Raymond John Zielinski - Portage MI

The Upjohn Company - Kalamazoo MI

A61K 3140

514422

This invention concerns a method for killing internal parasites, especially nematodes, trematodes and cestodes affecting warm blooded animals such as sheep, cattle, swine, goats, dogs, cats, horses and humans as well as poultry by administering an effective amount of dioxapyrrolomycin of the formula I. Anthelmintic compositions of dioxapyrrolomycin and an improvement in the process of preparation of dioxapyrrolomycin are also provided. ##STR1##.